Business
Award of New Innovate UK Grant
Award of New Innovate UK Grant.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 6050H Physiomics PLC 14 March 2018 \n\n \nPhysiomics plc \n(\"Physiomics\") or (\"the Company\")\n \nAward of New Innovate UK Grant\n \nFeasibility study to optimise individual patient dosing in prostate cancer in new era of precision medicine\n \nPhysiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens, is pleased to announce that is has been awarded a new grant by Innovate UK, the UK's innovation agency. The grant, awarded as part of Innovate UK's Precision Medicine competition, will support the project \"Prostate Cancer Chemotherapy Precision Dosing\".\nThe total cost of the project is expected to be £97k, the majority of which relates to internal staff costs. Innovate UK will contribute a total of £68k to the project over a nine-month period commencing April 2018.\nPrecision or personalised medicine heralds a new era of cancer care where each patient receives the right drug at the right dose and time specific to their needs. Currently, the choice of chemotherapy dose in both clinical practice and clinical trials is usually based on Body Surface Area (BSA) which works at a population level but can lead to under or over dosing of individual patients.\nFocusing on prostate cancer in this feasibility study, our goal is to develop an algorithm and demonstrator tool to optimise the individual patient dosing of a drug commonly used to treat prostate cancer. We will draw on a range of drug, tumour and patient data routinely monitored in current clinical pratice and use Physiomics technologies and capabilities (clinical PK/PD, toxicity and Virtual Tumour models) to build a novel predictive tool.\nThe outputs of the project will require further work before they can be commercialised, however we see two potential markets for the concept. Firstly in pharmaceutical clinical trials to help design better drug regimens for specific sub-populations of patients. Secondly, in clinical practice to optimise the dosing of prostate cancer patients, and ultimately to deliver improved cancer care. To support us in the evaulation of the potential of the tool in real-world clinical settings we will be working with the Oxford Academic Health Science Network.\nDr Jim Millen, CEO, said \"Having recently comp...